# Treatment for Completers of the Study B7A-MC-MBCM

> **NCT00266695** · PHASE3 · COMPLETED · sponsor: **Chromaderm, Inc.** · enrollment: 203 (actual)

## Conditions studied

- Diabetic Retinopathy

## Interventions

- **DRUG:** Ruboxistaurin

## Key facts

- **NCT ID:** NCT00266695
- **Lead sponsor:** Chromaderm, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2016-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00266695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00266695, "Treatment for Completers of the Study B7A-MC-MBCM". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00266695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*